List of Antibodies Companies in Virginia - 6

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

TheBEI ResourcesRepository is a central repository, established by the National Institute of Allergy and Infectious Disease, that supplies organisms and reagents, such asSARS-CoV-2, to the broad community of microbiology and infectious diseases researchers.

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

Engineered BioPharmaceuticals, Inc. is a state-of-the-art biotechnology company focused on advancing dry powder pharmaceutical manufacturing and delivery through Atmospheric Spray Freeze Drying (ASFD) technology. Manufacturing dry powder pharmaceuticals using the ASFD process offers many possibilities including increased stability and shelf life of drug formulations, ability to store at room temperature, reduced weight and bulk, and the ability to facilitate the development of novel self-administration methods of delivery, such as nasal and pulmonary. A significant advantage of the ASFD process compared to its competitors is that it allows pharmaceutical powders to be "engineered" for a wide variety of final use applications. A specific final particle size is easily achieved by adjusting the droplet diameter via the spray nozzle. In addition, the density, and thereby the aerodynamic size, can be adjusted independent of the geometric diameter by altering the starting solute concentration. With our population demanding sophisticated therapeutics to extend life expectancy and improve quality of life, contrasted with the dire need to reduce spiraling healthcare costs, there is enormous pressure and opportunity for the pharmaceutical industry to embrace new technologies that answer the call. We are excited about the innovative work taking place at eBio to advance the field and look forward to the opportunity to use ASFD technology to impact the future of medicine.

LumaCyte’s advanced real-time bioanalytics platform, Radiance®, is a label-free, single cell approach for quantitative characterization of innate cellular responses, without the need for antibody or genetic labeling. This revolutionary technology utilizes Laser Force Cytology™ (LFC) to measure subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells in response to their environment and/or treatment.

NEXT Bio-Research, Services continues a 23 year history in providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors. We also provide medical testing services to physicians using state-of-the-art platforms. NEXT Bio-Research Services was founded by three long standing colleagues who have worked together these past 23 years and collectively represent more than 100 years’ experience in life science technologies. NEXT Bio-Research Services is focused in (1) clinical testing using molecular and biochemical techniques; (2) molecular genetics of pharmacogenomics and cancer; (3) contract research in drug discovery and development with private sector customers; and (4) laboratory support of human clinical trials. We function as an extension of your own laboratory in helping you to bring their products from discovery to market. Our laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) act and our contract research services are offered individually or can be integrated to support product development from discovery to market with full regulatory support under FDA GLP Guidelines 21 CFR 58.